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Objectives: To investigate the function of immunomarkers CK7, CK20, CK17, CDX2,
MUC1, and MUC2 in the identification of primary ampullary carcinoma mixed
subtype.
Methods: Forty‐two cases of primary ampullary carcinoma were performed by
immunohistochemical studies. The correlation between the mixed subtype and the
other two subtypes and patient survival data was analyzed using the SPSS 16.0
statistical software.
Results: Among 42 cases, 12 (28.6%) cases were classified as mixed subtype,
which showed variable expression patterns: 91.7% (11/12) for CK7, 83.3% (10/
12) for CK20; 66.7% (8/12) for CK17, CDX2, and MUC1; and 50% (6/12) for
MUC2. Ten (83.3%) mixed types coexpressed four or more immunomarkers.
Eight (19%) intestinal subtypes mainly showed a positive expression of CK20,
CDX2, and MUC2. Twenty‐two (52.4%) pancreaticobiliary subtypes showed a
positive expression of CK7, MUC1, and CK17. Stages III and IV diseases in mixed
subtype (25%) and intestinal subtype (25%) were less than pancreaticobiliary
subtype(63.6%) (p = 0.039). Follow‐up data appeared to show a better
survival rate for patients with mixed subtype than those with pancreaticobiliary
subtypes.
Conclusion: Immunohistochemical staining provided a more reliable means of diagnosing
mixed ampulla carcinoma. Accurate subtyping of ampullary carcinoma is clinically
important to select effective chemotherapy regimens and to assess disease prognosis.
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1 | INTRODUCTION
Among all tumors of the digestive system, ampullary carcinoma is
relatively rare. It is commonly treated by pancreaticoduodenectomy
(Whipple procedure), which is one of the most complicated
operations in general surgery, carrying high postoperative complica-
tions and mortality. Accurate pathologic diagnosis is very important
for determining prognosis, selecting the treatment option, and
developing a chemotherapy regimen.
The ampulla of Vater is a unique structure formed by the union of
two different types of mucosa: the intestinal mucosa of the
duodenum and the pancreaticobiliary mucosa from the pancreatic
and common bile ducts. It is a hot spot for adenoma and
adenocarcinoma.1 Given the anatomic complexity of the structure,
the definition of ampullary carcinoma remains somewhat ambiguous.
As a result, carcinomas of the pancreatic head, distal common bile
duct, and second portion of duodenum may be misdiagnosed as
ampullary carcinoma. On the other hand, heterogeneous histologic
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phenotypes (intestinal, pancreaticobiliary, and mixed) are observed in
ampullary carcinomas.
In recently established guidelines, a tumor is designated an
ampullary primary only if the following criteria are met.2,3 First, its
epicenter is located in the lumen or wall of the distal ends (intra‐
ampullary component) of the common bile duct and/or pancreatic duct;
or at the papilla of Vater (ie, the junction of duodenal and ampullary
mucosae, as defined by the College of American Pathologists); or the
duodenal‐facing surface of the papilla (the ampullary protuberance). In
the latter circumstance, a tumor is designated an ampullary primary,
rather than duodenal, only if the ampullary orifice is clearly located
within the lesion. Second, the tumor epicenter or >75% of the bulk of
the tumor is within the ampulla.
A typical ampullary carcinoma may be diagnosed by endoscopy and
imaging modalities, but this may not always be the case in clinical
practice. Many cases have an insidious clinical course and patients are
often admitted due to obstructive jaundice. In addition, tumor tissue
origin cannot be precisely determined by endoscopy and imaging, but
knowing tissue origin is of great importance to treatment decision‐
making. The optimal chemotherapy regimen for ampullary carcinoma
differs according to the tissue origin. Histologically, ampullary carcinomas
are traditionally subclassified into pancreaticobiliary and intestinal
subtypes (Figure 1). Some retrospective studies have suggested that
the pancreatobiliary subtype is best treated with gemcitabine therapy,
while the intestinal subtype is better treated with a 5‐fluorouracil‐based
regimen.4
In addition to the pancreaticobiliary and intestinal subtypes, a
mixed subtype is recently recognized.4-7 This may partially explain
why some patients do not respond as predicted to treatment. The
prognosis and chemotherapy options for mixed subtype are still
being explored, but histopathologic subclassification of ampullary
carcinoma becomes more challenging. This is particularly true
when the tumor is poorly differentiated, which makes it more
difficult to subtype by morphology alone. To date, only scarce data
are available regarding the role of tumor markers in the
subclassification of ampullary carcinomas, especially for the mixed
subtype. The definition of ampullary carcinoma mixed subtype
remains unclear.
In the present study, we aimed to subclassify 42 cases of
ampullary carcinoma using a panel of six tumor markers, including
CK7, CK20, CK17, CDX2, MUC1, and MUC2. In particular, we
focused on examining the role of these markers in aiding the
histologic diagnosis of mixed subtype. The patient survival data were
analyzed to assess the correlation with different subtypes.
2 | MATERIALS AND METHODS
2.1 | Clinicopathologic data
A total of 42 cases of primary ampullary carcinoma from 2012 to 2018
were collected at the Peking University People's Hospital, including 22
males (52.4%) and 20 females (47.6%). All of the patient information was
complete and the follow‐up data were available. There were 6 well‐
differentiated adenocarcinomas, 19 moderately differentiated adenocar-
cinomas, and 17 poorly differentiated adenocarcinomas. The median age
of patients was 61.8 ± 10.8 (range 42‐88) years. The median size of the
tumors was 2.2 ± 1.0 cm in diameter (ranging from 0.8 to 4.5 cm). Using
the eighth edition American Joint Committee on Cancer (AJCC) TNM
staging system,8 6 cases were staged I, 17 staged II, 18 staged III, and 1
staged IV. Twelve cases showed lymph node metastasis (N1=10 cases;
N2=2 cases). The study was approved by the Hospital Ethics Review
Committee.
2.2 | Immunohistochemistry
Immunohistochemistry was performed using the conventional streptavi-
din-perosidase (SP) method. Formalin‐fixed, paraffin‐embedded tissue
sections were deparaffinized and rehydrated with xylene and a series of
grades of alcohol. After epitope retrieval and inactivation of endogenous
peroxidase, sections were blocked with 10% normal goat serum for
30minutes and sequentially incubated with the CK7, CK20, CK17, CDX2,
MUC1, andMUC2 antibodies (purchased from Beijing Zhongshan Jinqiao
Biotechnology Co., Ltd., Beijing, China) and horseradish peroxidase–
conjugated antirabbit and anti‐mouse IgG. After washing, slides were
developed by the chromogen diaminobenzidine tetrahydrochloride,
followed by counterstaining with hematoxylin.
F IGURE 1 Traditionally, ampullary carcinomas are mainly subclassified into intestinal subtype (A) and pancreatobiliary subtype (B). HE,
×100. [Color figure can be viewed at wileyonlinelibrary.com]
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A summed score (A ×B) was calculated based on the proportion (A)
and intensity (B) of positively stained tumor cells. For A, 1 point was
assigned if <25% of tumor cells were positively stained, 2 points if 25 to
50%, and 3 points if >50%. Zero (0) point was assigned if there were no
positively stained tumor cells. For B, 1 point was assigned for light
yellow staining intensity (weak), 2 points for brownish yellow intensity
(intermediate), and 3 points for tan coloration (strong). If the sum of
A ×B was <4, the staining result was considered negative, whereas a
sum of ≥4 was considered positive.
2.3 | Statistical analysis
Data were analyzed for statistical significance using the χ2 test (SPSS,
Chicago, IL; Computer Resource Center). The overall survival of
patients with ampullary carcinomas in this study was analyzed using
a log‐rank test based on Kaplan‐Meier analyses with data V.16.0
software (SPSS, Chicago, IL; Computer Resource Center). A two‐
tailed P value < 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Expressions of CK7, CK20, CK17, CDX2,
MUC1, and MUC2 in ampullary carcinoma
We found that five of the six examined immunomarkers exhibited a
scattered spotty expression pattern in some ampullary carcinoma
cases, staining <25% tumor cells. MUC1 was an exception, which did
not show this pattern. CK7 exhibited a spotty expression rate of 8.3%
(1/12) only in mixed subtype carcinomas. Both CK17 and MUC2
showed scattered spotty expression in all three subtypes. CK20 and
CDX2 were expressed in both pancreaticobiliary and mixed subtypes
(Table 1, Figure 2). According to the experimental design of this
study, this form of discontinuous scattered focal expression was
considered negative (the sum of score [A × B] for this pattern is <4).
TABLE 1 Frequency of scattered spotty expression pattern of
CK7, CK20, CK17, CDX2, MUC1, and MUC2 in 42 cases of ampullary
carcinoma
Histopathologic subtype, n%
Intestinal Pancreaticobiliary Mixed
Immunomarker (n = 8) (n = 22) (n = 12)
CK7 0 (0) 0 (0) 1 (8.3)
CK17 5 (62.5) 1 (4.5) 3 (25)
MUC1 0 (0) 0 (0) 0 (0)
CK20 0 (0) 2 (9) 2 (16.7)
CDX2 0 (0) 8 (36.4) 2 (16.7)
MUC2 1 (12.5) 2 (9) 2 (16.7)
F IGURE 2 Scattered spotty expression pattern of CK17 (A), CK20 (B), CDX2 (C), and MUC2 (D) by immunohistochemistry observed in
ampullary carcinoma, which was considered negative. SP, ×100 [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 3 An example of mixed subtype of ampullary carcinoma showing simultaneous coexpression of all six immunomarkers, CK7 (A),
CK17 (B), MUC1 (C), CK20 (D), CDX2 (E) and MUC2 (F). SP, ×40 [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 4 An example of the mixed subtype of ampullary carcinoma showing simultaneous coexpression of CK7 (A), CK17 (B), CDX2(C), and
MUC2(D), the expression was often detected in only half of the tumor cells. SP, ×40 [Color figure can be viewed at wileyonlinelibrary.com]
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Among the 42 cases, eight (19%) were classified as the
intestinal subtype. These tumors showed positive expression of
both CK20 and CDX2 in 100% (8/8) of cases, and MUC2
expression in 62.5% (5/8). Both CK7 and CK17 were weakly
expressed in one case (12.5%). No positive expression of MUC1
was observed in this subtype.
A total of 22 cases (52.4%) were classified as the pancreaticobiliary
subtype. These tumors showed positive expression of both CK7 and
MUC1 in 100% of cases and positive expression of CK17 in 90.9%
(20/22). No positive expression of CK20, CDX2, and MUC2 was
observed in the pancreaticobiliary subtype.
Twelve cases (28.6%) were classified as the mixed subtype, which
contained various amounts of pancreaticobiliary and intestinal
components. In cases with poor tumor differentiation, it is difficult
to accurately classify on the basis of hematoxylin-eosin (HE)
morphology, but we were able to detect simultaneous coexpression
of various immunomarkers by immunohistochemistry. Specifically,
CK7 was positively expressed in 91.7% (11/12) of mixed subtype
carcinomas; CK20 in 83.3% (10/12); CK17, CDX2, and MUC1 each in
66.7% (8/12); and MUC2 in 50% (6/12). Among mixed subtypes, 25%
(3/12) coexpressed all six immunomarkers (Figure 3), 25% (3/12)
coexpressed five markers, 33.3% (4/12) coexpressed four markers, and
16.7% (2/12) coexpressed two markers. All coexpressed immunohis-
tochemical markers were from both the intestinal‐derived expression
group and the pancreaticobiliary‐derived expression group. In tumors
that coexpressed CK7, CK17, CDX2, and MUC2, the expression was
often detected in only half of the tumor cells (Figure 4). The detailed
immunohistochemical findings are presented in Table 2.
3.2 | Clinicopathological relationship and prognosis
of different pathological subtypes in 42 patients with
primary ampullary carcinoma
Among the 42 cases of primary ampullary carcinoma included in this
study, the pancreaticobiliary, intestinal, and mixed subtypes were not
associated with patient’s gender, patient’s age, tumor size, histologic
differentiation, pancreatic invasion, bile duct invasion, or depth of
duodenal invasion. However, the histologic subtypes significantly
differed with regard to the TNM stages of the tumors. Stage III + IV
tumors were more significantly rare in pancreaticobiliary subtype
(63.6%, 14/22) compared with intestinal subtype (25%, 2/8) and
mixed subtype (25%, 3/12) (χ2 = 6.508, P = 0.039).
During an average of 80 months of follow‐up after surgery, the
median survival time was 33.8 months ( ± 23.8 months) for all
patients. Survival rates were 87.5% (7/8) for the intestinal
subtype, 50% (11/22) for the pancreaticobiliary subtype, and
58.3% (5/7) for the mixed subtype. Although an overall statistical
analysis did not show significant differences in survival rates
among different subtypes, analysis of follow‐up data during the
first 60 months revealed the following survival ranking from the
lowest to the highest: pancreaticobiliary subtype < mixed sub-
type < intestinal subtype (Figure 5). It is highly likely that the
analysis of a larger number of cases would yield statistically
significant results (Table 3, Figure 5).
4 | DISCUSSION
Ampullary carcinoma reportedly accounts for about 0.5% of
malignant tumors of the digestive system, but the actual
TABLE 2 Frequency of CK7, CK20, CK17, CDX2, MUC1, and MUC2 expression in 42 cases of ampullary carcinoma
Intestinal, n (%) Pancreaticobiliary, n (%) Mixed, n (%)
Immunomarker Positive Negative Positive Negative Positive Negative
CK7 1 (12.5) 7 (87.5) 22 (100) 0 (0) 11 (91.7) 1 (8.3)
CK17 1 (12.5) 7 (87.5) 20 (90.9) 2 (0.09) 8 (66.7) 4 (33.3)
MUC1 0 (0) 8 (100) 22 (100) 0 (0) 8 (66.7) 4 (33.3)
CK20 8 (100) 0 (0) 0 (0) 22 (100) 10 (83.3) 2 (16.7)
CDX2 8 (100) 0 (0) 0 (0) 22 (100) 8 (66.7) 4 (33.3)
MUC2 5 (62.5) 3 (37.5) 0 (0) 22 (100) 6 (50) 6 (50)
F IGURE 5 Comparison of survival rates of patients with different
subtypes of ampullary carcinoma (blue—pancreaticobiliary subtype;
yellow—mixed subtype; green—intestinal subtype) [Color figure can
be viewed at wileyonlinelibrary.com]
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frequency may be higher. With a better understanding of the
definition of the ampulla of Vater, advances in endoscopic and
imaging techniques and more accurate pathologic diagnosis,
some of the cases that were previously misdiagnosed as
carcinomas of the pancreatic head or duodenum have now been
reclassified as ampullary carcinomas. Typical ampullary carcino-
ma can be diagnosed by imaging, particularly magnetic resonance
imaging (MRI) that has a high soft tissue resolution. It can be
combined with thin‐layer scanning to achieve a diagnostic
accuracy of 92.63%.9 However, imaging cannot determine tissue
origin and thus cannot help subclassification of ampullary
carcinoma. Ampullary carcinomas with typical histopathology
may be subclassified based on morphologic features recognized
on conventional HE slides. It is generally agreed that the
intestinal subtype of ampullary carcinoma is morphologically
similar to colorectal carcinoma—exhibiting interconnected tu-
bules, elongated glands, complex cribriform structures, or solid
nests, and commonly showing necrotic debris in the glandular
lumens.4,10,11 Tumor cells are typically columnar with
hyperchromatic and pseudostratified nuclei, and basophilic
cytoplasm, and may contain goblet cells. On the other hand, the
pancreaticobiliary subtype usually shows a wider spectrum of
histomorphology. Typical cases show simple or branching glands
or small solid cell nests. Tumor cells are typically cuboidal to low
columnar with rounded vesicular nuclei arranged in a single layer
in a desmoplastic stroma (Figure 1).
To date, the definition of mixed ampullary carcinoma remains
controversial. Different authors have proposed that the mixed subtype
be defined as when the pancreaticobiliary and intestinal subtypes each
constitute >10%,6 >20%,7 or >25% of the tumor.4 In our present study,
we found that the proportions of pancreaticobiliary and intestinal
components in mixed subtype ampullary carcinomas varied widely
among different cases, challenging the utility of a unified quantitative
standard. However, some pathologists have pointed out that it is
difficult to identify mixed ampullary cancer and to obtain a consistent
diagnosis between different observers.7 Several immunohistochemical
markers have been investigated for their usefulness in the subclassi-
fication of ampullary carcinomas,5,12,13 but there is no clear conclusion.
TABLE 3 Comparison of clinicopathologic features among different subtypes of ampullary carcinoma (n = 42)
Feature
Histopathologic subtype
χ2 P valueIntestinal (n = 8) Pancreaticobiliary (n = 22) Mixed (n = 12)
Sex
Male 3 14 5 2.402 0.301
Female 5 8 7
Age, y
≤ 60 4 10 7 0.517 0.772
＞60 4 12 5
Tumor size, cm
≤2 4 14 5 1.603 0.449
>2 4 8 7
Histologic differentiation
Well 2 2 2 7.486 0.112
Moderate 4 7 8
Poor 2 13 2
TNM Staging
Stage I + II 6 8 9 6.508 0.039
Stage III + IV 2 14 3
Pancreatic invasion
Yes 2 10 4 1.230 0.541
No 6 12 8
Common bile duct invasion
Yes 1 1 2 1.440 0.4879
No 7 21 10
Depth of duodenal invasion
No 0 2 2 9.373 0.154
Mucosa and submucosa 1 2 0
Muscularis propria 4 5 7
Serosa and subserosa 3 13 3
Follow‐up 3.864 0.145
Alive 1 11 5
Died 7 11 7
Survival time, mo 52.1 ± 8.3 42.2 ± 8.0 48.4 ± 9.1 47.245 0.504
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We propose that it may be more reliable to define mixed ampullary
carcinoma based on the expression patterns of immunomarkers by our
study, especially for poorly differentiated tumors. But the key issue is
our findings demonstrate that the methodology of evaluating
immunohistochemical staining has an important impact on the
interpretation of staining results. We observed that some markers
exhibited varying degrees of scattered spotty expression, which should
not be interpreted as the positive expression because this pattern
differs from the “normal expression pattern” that is more confluent
and contiguous (the sum of score (A + B) ≥ 4). It is also important to
distinguish tumor tissue from benign glands of the ampullary region
and to avoid interpreting positive staining in irregular benign glands as
tumorous. Bearing these in mind, we were able to classify ampullary
carcinomas into different subtypes based on their immunostaining
profiles. Specifically, CK7, CK17, and MUC1 are mainly markers of the
pancreaticobiliary subtype, while CK20, CDX2, and MUC2 are
primarily intestinal markers. All coexpressed immunohistochemical
markers were from both the intestinal‐derived expression group and
the pancreaticobiliary‐derived expression group indicated a mixed
subtype. Kohler et al5 found that the mixed subtypes simultaneously
express CK7, CK20, and CDX2. We found at least two immunomar-
kers coexpressions in the mixed subtypes; they were MUC1 and
MUC2, CK7 and MUC2, respectively. No combination of CK7 and
CK20 was found. It should be mentioned that 40% of our cases
included in this study are poorly differentiated. A clear separation
between pancreaticobiliary and intestinal subtypes is very difficult
based on histopathologic examination. Immunohistochemical stains
using the six antibody panels are of great help in this regard.
Immunohistochemistry thus provides a more reliable means to aid in
the subclassification of ampullary carcinoma, especially for poorly
differentiated mixed subtypes. This is the first time we have proposed
the identification of mixed subtypes by immunohistochemistry.
Of the 42 patients with ampullary carcinoma, only 4 (9.5%) were
under the age of 50 years, indicating that ampullary carcinoma usually
occurs among older patients. Statistical analysis of our data showed that
different subtypes of ampullary carcinoma were significantly associated
with the TNM staging of tumors (χ2 = 6.508, P=0.039). These results
suggest that the pancreaticobiliary subtype is potentially more aggressive
biologically than mixed subtype. We have also observed different survival
rates in patients with different subtypes, although the differences were
not statistically significant possibly due to the relatively small sample size.
Nevertheless, the survival curves for the first 60 months after surgery
showed patients with mixed subtype in the intermediate survival rate,
consistent with Kohler's report.7
5 | CONCLUSIONS
In summary, our study provides additional evidence to support
immunohistochemistry using a panel of selected antibodies (CK7,
CK20, CK17, CDX2, MUC1, and MUC2) as a useful tool to aid in the
identification of ampullary carcinomas mixed subtypes. Accurate
subclassification is of great importance to patient care and prognosis
assessment.
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